![]() We are writing to you today to set the record straight following the web of false and misleading statements made recently by a group of individuals that is trying to take control of the Board of Directors (the "Board") of AIM ImmunoTech (the "Activist Group"). (NYSE: American AIM) ("AIM" or the "Company") today issued a letter to shareholders to correct the record around recent false and misleading statements made by Jonathan Jorgl and other members of an activist group, who have attempted to nominate two director candidates for election as directors at the Company’s 2022 Annual Meeting of Shareholders and are seeking to take control of the Board. OCALA, Fla., October 26, 2022-( BUSINESS WIRE)-The Board of Directors ("Board") of AIM ImmunoTech Inc. Urges Shareholders to Continue to Support Company’s Positive Momentum Towards Value Creation by Voting on the WHITE Proxy Card to Re-Elect AIM’s Current Directors ![]() Group Concealed that Its Campaign Was Orchestrated by One Convicted Felon and Financed by Another Criminal – Until Forced to Do So in Context of Litigation Highlights Evidence of Group’s Scheme to Have Jorgl Serve as the "Face of the Activist" to Help Them "Get Control" Without Paying a Premium to All Shareholders Food and Drug Administration.Corrects the Record Regarding Activist Group’s False and Misleading Statements Developing Products for Rare Diseases & Conditions. CDC centers for Disease Control and Prevention. Additionally, Ampligen is approved in Argentina for the treatment of severe chronic fatigue syndrome (CFS) and is currently being evaluated in many aspects of SARS-CoV-2/COVID-19 myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Post COVID Conditions.įor more information, please visit and connect with the Company on Twitter, LinkedIn, and Facebook.ġ (October 2022). The Company also has multiple ongoing clinical trials to evaluate Ampligen as a combinational therapy for the treatment of a variety of solid tumor types both underway and planned at major cancer research centers. The Company plans to conduct an intranasal study of Ampligen to potentially enhance and expand natural immunity.Īmpligen is currently being used as a monotherapy to treat pancreatic cancer patients in an Early Access Program (EAP) approved by the Inspectorate of Healthcare in the Netherlands at Erasmus Medical Center and AIM has commenced a Phase 2 clinical study in 2022. AIM is currently evaluating the safety and effectiveness of intravenous Ampligen to reduce replication of SARS-CoV-2 virus from upper airway in patients in an ongoing Phase 1/2 study for the treatment of COVID-19 cancer patients. The prior studies of Ampligen in SARS-CoV-1 animal experimentation may predict similar protective effects against SARS-CoV-2. The Company has conducted experiments in SARS-CoV-2 showing Ampligen has a powerful impact on viral replication. 1 Previous animal studies yielded positive results utilizing Ampligen in Western Equine Encephalitis Virus, Ebola, Vaccinia Virus (which is used in the manufacture of smallpox vaccine) and SARS-CoV-1. ![]() J.D., Chief Executive Officer of AIM ImmunoTech.Įbola virus disease (EVD) is a rare but severe, deadly disease causing a multitude of symptoms including fever, gastrointestinal issues, aches, and bruising. While Ebola is not a primary focus for the Company at the moment, this provides further validation as well as optionality as we determine the next steps for this program moving forward,” commented Thomas K. We continue to be encouraged by the promising results Ampligen has demonstrated to date across a number of indications where there remains significant unmet need. “Receiving Orphan Drug Designation for Ampligen for the treatment of Ebola from the FDA is a testament to the depth and breadth of the potential with Ampligen. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Ampligen ® (rintatolimod) for the treatment of Ebola virus disease.Īmpligen is AIM’s dsRNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced the U.S. 02, 2022 (GLOBE NEWSWIRE) - AIM ImmunoTech Inc. Ampligen ® (rintatolimod) is an immuno-modulator with broad spectrum activity currently being evaluated for the treatment of globally important cancers, viral diseases and disorders of the immune systemĪmpligen has demonstrated positive results for the treatment of Ebola in previously conducted animal studies
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |